Amgen: GALACTIC-HF Trial Meets Primary Composite Endpoint; Fails To Meet Secondary Endpoint

Amgen (AMGN), Cytokinetics, Incorporated (CYTK) and Servier announced topline results from GALACTIC-HF, a phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure with reduced ejection fraction. The company said the results of GALACTIC-HF showed that treatment with omecamtiv mecarbil achieved the primary composite efficacy endpoint and demonstrated a statistically significant effect to reduce cardiovascular death or heart failure events compared to placebo. No reduction in the secondary endpoint of cardiovascular death was observed in the trial.

The results from GALACTIC-HF will be presented at the American Heart Association Scientific Sessions 2020, in a virtual Late Breaking Clinical Trial session on November 13.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Bea Lydecker's Naturals, Inc. is recalling six Living Free brand dietary supplement products citing undeclared soy lecithin, the U.S. Food and Drug Administration said. According to the agency, the labels declare lecithin but do not declare soy lecithin. Investment banking major Morgan Stanley plans to block employees and clients who are not fully vaccinated against COVID-19 from entering its New York offices, the Financial Times reported citing an internal memo. The policy is expected to come into effect on July 12, and all unvaccinated employees will lose building access from then onwards. Oklahoma City, Oklahoma -based Prairie Wolf Spirits, Inc. is recalling certain Prairie Wolf Distillery hand sanitizer packaged in containers that resemble water bottles, the U.S. Food and Drug Administration said. The product poses a risk of ingestion. The recall involves all lots of Prairie Wolf Distillery hand sanitizer packaged in 16.9 fluid ounce and 20 fluid ounce containers.
Follow RTT